NCT05934513

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 95 (estimated)
• Sponsor: Genfleet Therapeutics (Shanghai) Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma

Conditions

• Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Interventions

Type	Name	Description
DRUG	GFH009	patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion

Timeline

• Start date: 2023-09-06
• Primary completion: 2025-12-30
• Completion: 2026-06-30
• First posted: 2023-07-07
• Last updated: 2024-12-13

Locations

1 site across 1 country: China